Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

The FDA approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon ...

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment ...

Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, ...